Nanoscale cancer therapeutics

Nanotherapeutics: Drug Delivery Concepts in Nanoscience

Volumn , Issue , 2008, Pages 93-124

  Pellequer, Yann ^a   Lamprecht, Alf ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960307603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814241168     Document Type: Chapter

References (100)

1. Akamo, Y., Mizuno, I., Yotsuyanagi, T., Ichino, T., Tanimoto, N., Yamamoto, T., Nagata, M., Takeyama, H., Shinagawa, N., Yura, J. and et al. (1994). Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma. Jpn. J. Cancer Res., 85, pp. 652-658.
2. Ameller, T., Marsaud, V., Legrand, P., Gref, R. and Renoir, J. M. (2003). In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668. Int. J. Cancer, 106, pp. 446-454.
3. Arap, W., Pasqualini, R. and Ruoslahti, E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279, pp. 377-380.
4. Barraud, L., Merle, P., Soma, E., Lefrançois, L., Guerret, S., Chevallier, M., Dubernet, c., Couvreur, P., Trepo, C. and Vitvitski, L. (2005). Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol., 42, pp. 736-743.
5. Batist G., Ramakrishman, G., Rao, C. S., Chandrasekharan, A, Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A, Nair, M. K., Hoelzer, K., Tkaczuk, K., Park, Y. C. and Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol., 19, pp. 1444-1454.
6. Begley, D. J. (2004). Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther., 104, pp. 29-45.
7. Brigger, I., Dubernet, C. and Couvreur, P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 54, pp. 631-651.
8. Chiannilku1chai, N., Ammoury, N., Caillou, B., Devissaguet, J. P. and Couvreur, P. (1990). Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemother. Pharmacol., 26, pp. 122-126.
9. Choudhury, A., Charo, J. and Parapuram, S. K. Hunt, R. c., Hunt, D. M., Seliger, B. and Kiessling, R. (2004). Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int. J. Cancer, 108, pp. 71-77.
10. Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A. and Forni, F. (2005). Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Rel., 108, pp. 84-96.
11. Di Bella, N. J, Khan, M. M., Dakhil, S. R., Logie, K. W., Marsland, T. A, Weinstein, R. E., Mirabel, M. Y. and Asmar, L. (2003). Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: A phase II multicenter study. Clin. Lymphoma, 3, pp. 235-240.
12. Dvorak, H. F., Nagy, J. A, Dvorak, J. T. and Dvorak, A M. (1988). Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133, pp. 95-109.
13. EI-Aneed, A. (2004). An overview of current delivery systems in cancer gene therapy. J. Control. Rel., 94, pp. 1-14.
14. Errnacora, E., Michieli, M., Pea, F., Visani, G., Bucalossi, A and Russo, D. (2000). Liposome encapsulated daunorubicin (daunoxome) for acute leukaemia. Haematologica, 85, pp. 324-325.
15. Estey, E., Thall, P. F., Mehta, K., Rosenblum, M., Brewer, T. and Simmons, V. (1996). Alterations in tretinoin pharmacokinetics following administration of liposomal alltrans- Retinoic acid. Blood, 87, pp. 3650-3654.
16. Fassas, A, Buffels, R., Anagnostopoulos, A, Gacos, E., Vadikolia, C., Haloudis, P. and Kaloyannidis, P. (2002). Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: A phase I-II study. Br. J. Haematol., 116, pp. 308-315.
17. Fujisaka, Y., Horiike, A., Shimizu, T., Yamamoto, N., Yamada, Y. and Tamura, T. (2006). Phase I clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors. lpn. J. Clin. Oncol., 36, pp. 768-774.
18. Gabizon, A (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res., 52, pp. 891-896.
19. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A and Barenholz, Y. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res., 54, pp. 987-992.
20. Gabizon, A, Peretz, T., Sulkes, A, Amselem, S., Ben-Yosef, R., Ben-Baruch, N., Catane, R., Biran, S. and Barenholz, Y. (1989). Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur. J. Cancer Clin. Oncol., 25, pp. 1795-1803.
21. Gao, Z., Fain, H. D. and Rapoport, N. (2004). Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol. Pharm., 1, pp. 317-330.
22. Garcion, E., Lamprecht, A, Heurtault, B., Aubert-Pouessel, A, Denizot, B., Menei, P. and Benoît, J. P. (2006). A new generation of anticancer, drug-loaded, colloidal vectors reverses multi drug resistance in glioma and reduces tumour progression in rats. Mol. Cancer Therap., 5, pp. 1710-1722.
23. Gelderblom, H., Verweij, J., Nooter, K. and Sparreboom, A (2001). E. L. Cremaphor: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 37, pp. 1590-1598.
24. Gelmon, N. L., Tolcher, A, Diab, A R., Bally, M. B., Embree, L., Hudon, N., Dedhar, C., Ayers, D., Eisen, A., Melosky, B., Burge, C., Logan P. and Mayer, L. D. (1999). Phase I study of vincristine. J. Clin. Oncol., 17, pp. 697-705.
25. Giles, F. J., Tallman, M. S., Garcia-Manero, G., Cortes, J. E., Thomas, D. A., Wierda, W. G., Verstovsek, S., Hamilton, M., Barrett, E., Albitar, M. and Kantarjian, H. M. (2004). Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal mulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukaemia. Cancer, 100, pp. 1449-1458.
26. Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., Lacave, A. J. (2001). Recurrent epithelial ovarian carcinoma: a randomized phase II! study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oneal., 19, pp. 3312- 3322.
27. Hayes, M. E., Drummond, D. C. and Kirpotin, D. B., Zheng, W. W., Noble, C. O., Park, J. W., Marks, J. D., Benz, C. C. and Hong, K. (2006). Genospheres: selfassembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene. Ther., 13, pp. 646-651.
28. Heidenreich, A., Sommer, F., Ohlmann, C. H., Schrader, A. J., Olbert, P., Goecke, J. and Engelmann, U. H. (2004). Prospective randomized Phase I! trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer, 101, pp. 948-956.
29. Hillery, A. M. (2000). New liposomal formulation of vincristine for non-Hodgkin's lymphoma. Pharm. Sci. Technolo. Today, 3, pp. 79-80.
30. Hitzmann, C. J., Wattenberg, L. W. and Wiedmann, T. S. (2006). Pharmacokinetics of 5- fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J. Pharm. Sci., 95, pp. 1196-1211.
31. Hubert, A., Lyass, O., Pode, D. and Gabizon, A. (2000). Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs, 11, pp. 123-127.
32. Ibrahim, N. K., Samuels, B. and Page, R., Doval, D., Patel, K M., Rao, S. C., Nair, M. K, Bhar, P., Desai, N. and Hortobagyi, G. N. (2005) Multicenter phase I! trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oneal., 23, pp. 6019-6026.
33. Ishida, O., Maruyama, K, Tanahashi, H., Iwatsuru, M., Sasaki, K, Eriguchi, M. and Yanagie, H. (2001). Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res., 18, pp. 1042-1048.
34. Jain, R. K (2001). Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Rel., 74, pp. 7-25.
35. Kawakami, S., Opanasopit, P., Yokoyama, M., Chansri, N., Yamamoto, T., Okano, T., Yamashita, F. and Hashida, M. (2005). Biodistribution characteristics of all-transRetinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. J. Pharm. Sci., 94, pp. 2606-2615.
36. Kim, E. S., Lu, C., Khuri, F. R., Tonda, M., Glisson, B. S., Liu, D., Jung, M., Hong, W. K and Herbst, R. S. (2001). A phase I! study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer, 34, pp. 427-432.
37. Kong, G., Braun, R. D. and Dewhirst, M. W. (2000). Hyperthermia enables tumorspecific nanoparticle delivery: effect of particle size. Cancer Res., 60, pp.4440- 4445.
38. Koning, G. A., Morselt, H. W., Gorter, A., Allen, T. M., Zalipsky, S., Scherphof, G. L. and Kamps, J. A. (2003). Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparison. Pharm. Res., 20, pp.1249-1257.
39. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelprina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H. and Begley, D. J. (2003). Direct evidence that polysorbate-80- coated poly(butyl cyanoacrylate) nanopaticles deliver drugs to the CNS via specific mechanisms requiring prior binding of the drug to the nanoparticles. Pharm. Res. 20, pp. 409-416.
40. Kreuter, J., Tauber, U. and Illi, V. (1979). Distribution and elimination of poly(methyl-2- 14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J. Pharm. Sci., 68, pp. 1443-1447.
41. Krishna, R., and Mayer, L. D. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 11, pp. 265-283.
42. Lacoeuille, F., Hindre, F., Moal, F., Passirani, C, Couturier, O., Calès, P., Le Jeune J. J., Lamprecht, A. and Benoît J. P. (2007) In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel, Int. J. Pharm., in press.
43. Lamprecht, A. and Benoit, J. P. (2006). Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Rel., 112, pp. 208-213.
44. Law, T. M., Mencel, P. and Motzer, R. J. (1994). Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs, 12, pp. 323-325.
45. Lee, C C, Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Frechet, J. M., Dy, E. E. and Szoka, F. C. (2006). A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci., 103, pp. 16649-16654.
46. Leighl, N. B., Burkes, R. L., Dancey, J. E., Lopez, P. G., Higgins, B. P., David Walde, P. L., Rudinskas, L. C, Rahim, Y. H., Rodgers, A., Pond, G. R. and Shepherd, F. A. (2003). A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. Clin. Lung. Cancer, 5, pp. 107- 112.
47. Lu, H., Li, B., Kang, Y., Jiang, W., Huang, Q., Chen, Q., Li, L. and Xu, C (2007). Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother. Pharmacol., 59, pp. 175-181.
48. Lukyanov, A N., Gao, Z., Mazzola, L. and Torchilin, V. P. (2002). Polyethylene glycoldiacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice, Pharm. Res., 19, pp. 1424-1429.
49. Lyass, O., Uziely, B., Ben Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G. and Gabizon, A. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer, 89, pp. 1037-1047.
50. Madhankumar, A. B., Slagle-Webb, B., Mintz, A, Sheehan, J. M. and Connor, J. R. (2006). Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. Mol. Cancer Ther., 5, pp. 3162-3169.
51. Maeda, H. and Matsumura, Y. (2000). Tumoritripic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carr. Syst., 6, pp. 193-210.
52. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel., 65, pp. 271-284.
53. Maruyama, K., Ishida, O., Takizawa, T. and Moribe, K. (1999). Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev., 40, pp. 89-102.
54. Moghimi, S. M., Hunter, A C. and Murray, J. C. (2001). Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol. Rev., 53, pp. 283-318.
55. Moreira, J. N., Ishida, T., Gaspar, R., and Allen, T. M. (2002). Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm. Res., 19, pp. 265-269.
56. Muggia, F. M. (1997). Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs, 54, Suppl. 4, pp.22-29.
57. Nagami, H., Matsumoto, Y. and Ueoka, R. (2006). Chemotherapy with hybrid liposomes for lymphoma without drugs in vivo. Int. J. Pharm., 315, pp. 167-172.
58. Namiki, Y., Namiki. T, Date, M., Yanagihara, K., Yashiro, M. and Takahashi, H. (2004). Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome. Pharmacal. Res., 50(1), pp. 65-76.
59. Neelapu, S. S., Baskar, S., Gause, B. L., Kobrin, C. B., Watson, T. M., Frye, A R., Pennington, R., Harvey, L., Jaffe, E. S., Robb, R. J., Popescu, M. C. and Kwak, L. W. (2004). Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res., 10, pp. 8309-8317.
60. Neuwelt, E. A. (2004). Mechanisms of disease: the blood-brain barrier. Neurosurgery, 54, pp. 131-142.
61. Newman, M. S., Colbem, G. T., Working, P. K., Engbers C. and Amantea, M. A. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumorbearing mice. Cancer Chemother. Pharmacal., 43, pp. 1-7.
62. Newton, H. B. (2006). Advances in strategies to improve drug delivery to brain tumors. Expert Rev. Neurother., 6, pp. 1495-1509.
63. Nikitin, A. Y., Juarez-Perez, M. I., Li, S., Huang, L. and Lee, W. H. (1999). RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/-mice. Proc. Natl. Acad. Sci., 96, pp. 3916-3921.
64. Nishiyama, N., Okazaki, S., Cabral, H., Miyamoto, M., Kato, Y., Sugiyama, Y., Nishio, K., Matsumura, Y. and Kataoka, K. (2003). Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res., 63, pp. 8977-83.
65. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T. and Maeda, H. (1998). Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res., 89, pp. 307-314.
66. Numico, G., Castiglione, F., Granetto, C., Garrone, O., Mariani, G., Costanzo, G. D., Ciura, P. L., Gasco, M., Ostellino, O., Porcile, G. and Merlano, M. (2002). Singleagent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated nonsmall cell lung cancer patients: a pilot trial. Lung Cancer, 35, pp. 59-64.
67. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 15, pp. 440-449.
68. Osborne, C., Wilson, P. and Tripathy, D. (2004). Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist, 9, pp.36l-377.
69. Otterson, G. A, Villalona-Calero, M. A, Sharma, S., Kris, M. G., Imondi, A., Gerber, M., White, D. A, Ratain, M. J., Schiller, J. H., Sandler, A, Kraut, M., Mani, S. and Murren, J. R. (2007). Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin. Cancer Res., 13, pp. 1246-1252.
70. Ozpolat, B. and Lopez-Berestein, G. (2003). Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (atra) and orally administered atra in healthy volunteers. J. Pharm. Pharmaceut. Sci., 6, pp. 292-301.
71. Ozpolat, B., Mehta, K., Tari, A. M. and Lopez-Berestein, G. (2002). All-trans-Retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukaemia. Am. J. Hematol., 70, pp. 39-47.
72. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. c., Lasic, D. D., Redemann, C. and Martin, F. J. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci., 88, pp. 11460-11464.
73. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K., Woodle, M. C., Lasic, D. D., Redemann, C. and Martin, M. F. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci., 88, pp. 11460-11464.
74. Prabha, S. and Labhasetwar, V. (2004). Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells. Mol. Pharm., 1, pp. 211-219.
75. Reddy, G. R., Bhojani, M. S., McConville, P., Moody, J., Moffat, B. A., Hall, D. E., Kim, G., Koo, Y. E., Woolliscroft, M. J., Sugai, J. V., Johnson, T. D., Philbert, M. A., Kopelman, R., RehemtulIa, A. and Ross, B. D. (2006). Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res., 12, pp.6677-6686.
76. Reddy, H. L., Adhikari, J. S., Dwarakanath, B. S., Sharma, R. K. and Murthy, R. R. (2006). Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma tumor bearing mice. AAPS J., 2, pp. E254-262.
77. Reddy, H. L., Sharma, R. K., Chuttani, K., Mishra, A. K. and Murthy, R. R. (2005). Influence of administration route on tumour uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice. J. Control. Rel., 105, pp. 185-198.
78. Romond, E. H., Perez, E. A. and Bryant, J. et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med., 353, pp.1673-1684.
79. Rose, P. G. (2005). Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist, 10, pp. 205-214.
80. Ruoslahti, E., Duza, T. and Zhang, L. (2005). Vascular homing peptides with cellpenetrating properties, Curro Pharm. Des., 11, pp. 3655-3660.
81. Sapra, P., Moase, E. H., Ma, J. and Allen, T. M. (2004). Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin via Anti-CD19 IgG2a or Fab' fragments. Clin. Cancer Res., 10, pp. 100-1111.
82. Sarris, A. H., Hagemeister, F., Romaguera, J., Rodriguez, M. A., McLaughlin, P., Tsimberidou, A. M., Medeiros, L. J., Samuels, B., Pate, O., Oholendt, M., Kantarjian, H., Burge, C. and Cabanillas, F. (2000). Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial. Ann. Oncol., 11, pp. 69-72.
83. Schiffelers, R. M., Koning, G. A., Hagen, T. L. M., Fens, M. H. A. M., Schraa, A. J., Janssen, A. P. C. A., Kok, R. J., Molema, G. and Storm, G. (2003). Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Rei., 91, pp. 115-122.
84. Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Helene, C., Saison-Behmoaras, T. (1994). Antisense oligonucleotides adsorbed to polyalkyIcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci., 91, pp. 10460-10464.
85. Shenoy, D. B. and Amiji, M. M. (2005). Poly(ethylene oxide)-modified poly(epsiloncaprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 293, pp. 261-270.
86. Singh, M., Ghose, T., Mezei, M., Belitsky, P. (1991). Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumor model. Cancer Lett., 56, pp. 97-102.
87. Skubitz, K. M. (2002). Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer. Invest. New Drugs, 20, pp. 101-104.
88. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A, Fleming, T., Eierrnann, W., Wolter, J., Pegram, M., Baselga, J. and Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344, pp. 783-792.
89. Sparreboom, A, Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A, Beals, B., Figg, W. D., Hawkins, M. and Desai, N. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res., 11, pp. 4136-4143.
90. Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V. and Stathopoulos, J. G. (2005). Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol. Rep., 13, pp. 589-595.
91. Steiniger, S. C., Kreuter, J., Khalansky, AS., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K D. and Gelperina, S. (2004). Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles, Int. J. Cancer, 109, pp. 759-767.
92. Sudimack, J. J., Adams, D., Rotaru, J., Shukla, S., Yan, J., Sekido, M., Barth, R. F., Tjarks, W. and Lee, R. J. (2002). Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy. Pharm. Res., 19, pp. 1502-1508.
93. Suzuki, S., Kawakami, S., Chansri, N., Yamashita, F. and Hashida, M. (2006). Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes.J. Control. Rel., 116, pp. 58-63.
94. Tomkinson, B., Bendele, R., Giles, F. J., Brown, E., Gray, A, Hart, K, LeRay, J. D., Meyer, D., Pelanne, M. and Emerson, D. L. (2003). OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL. Leuk. Res., 27, pp. 1039-1050.
95. Torchilin, V. P., Lukyanov, A N. and Gao, Z. (2003). Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci., 100, pp. 6039-6044.
96. Tulpule, A., Rarick, M. U., Kolitz, J., Bernstein, J., Myers, A., Buchanan, L. A., Espina, B. M., Traynor, A, Letzer, J., Justice, G. R., McDonald, D., Roberts, L., Boswell, W., Nathwani, B. and Levine, A. M. (2001). Liposoma1 daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann. Oncol., 12, pp. 457-462.
97. Veno, N. T., Bartho1omeusz, C., Xia, W., Anklesaria, P., Bruckheimer, E. M., Mebel, E., Paul, R., Li, S., Yo, G. H., Huang, L. and Hung, M. C. (2002). Systemic gene therapy in human xenograft tumor models by liposoma1 delivery of the E1A gene. Cancer Res., 62, pp. 6712-6716.
98. Verdiere, A. C., Dubernet, C., Nemati, F., Soma, E., Appel, M., Ferte, J., Bernard, S., Puisieux, F. and Couvreur, P. (1997). Reversion of multi drug resistance with polya1ky1cyanoacry1ate nanopartic1es: towards a mechanism of action. Br. J. Cancer, 76, pp. 198-205.
99. Yan, D. H., Chang, L. S. and Hung, M. C. (1991). Repressed expression of the HER-2/cerbB-2 proto-oncogene by the adenovirus E1 a gene products. Oncogene, 6, pp.343-345.
100. Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K. and Kataoka, K. (1999). Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. J. Drug Target., 7, pp. 171-186.